Showing results (51-60 of 70) with videos related to
Sort By:
Pageof 7
Journal of Immunology (Baltimore, Md. : 1950)|July 15, 1994
T lymphocyte T cell-B cell-activating molecule/CD40-L molecules induce normal B cells or chronic lymphocytic leukemia B cells to express CD80 (B7/BB-1) and enhance their costimulatory activityM J Yellin, J Sinning, L R Covey, et al.Molecular Immunology|November 1, 1991
A single amino acid substitution in a common African allele of the CD4 molecule ablates binding of the monoclonal antibody, OKT4S Lederman, J A DeMartino, B L Daugherty, et al.Blood Advances|May 8, 2020
Safety and activity of varlilumab, a novel and first-in-class agonist anti-CD27 antibody, for hematologic malignanciesStephen M Ansell, Ian Flinn, Matthew H Taylor, et al.International Journal of Cancer|December 16, 1997
Non-Hodgkin's lymphoma among people with AIDS: incidence, presentation and public health burden. AIDS/Cancer Study GroupT R Coté, R J Biggar, P S Rosenberg, et al.Investigational New Drugs|January 19, 2010
A phase II multicenter study of ipilimumab with or without dacarbazine in chemotherapy-naïve patients with advanced melanomaEvan M Hersh, Steven J O'Day, John Powderly, et al.Journal of Immunotherapy (Hagerstown, Md. : 1997)|June 27, 2006
Intrapatient dose escalation of anti-CTLA-4 antibody in patients with metastatic melanomaAjay V Maker, James C Yang, Richard M Sherry, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 3, 2017
Safety and Activity of Varlilumab, a Novel and First-in-Class Agonist Anti-CD27 Antibody, in Patients With Advanced Solid TumorsHoward A Burris, Jeffrey R Infante, Stephen M Ansell, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 10, 2005
Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4Peter Attia, Giao Q Phan, Ajay V Maker, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 8, 2015
EMERGE: A Randomized Phase II Study of the Antibody-Drug Conjugate Glembatumumab Vedotin in Advanced Glycoprotein NMB-Expressing Breast CancerDenise A Yardley, Robert Weaver, Michelle E Melisko, et al.The Lancet. Oncology|August 29, 2017
Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trialMichael Weller, Nicholas Butowski, David D Tran, et al.Pageof 7